Bupropion hydrochloride extended-release tablets are widely prescribed for the treatment of major depressive disorder and for ...

Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...

The medication is widely prescribed for the treatment of major depressive disorder and for the prevention of seasonal ...

Granules India's US subsidiary receives FDA approval for generic Bupropion Hydrochloride Extended-Release Tablets, expanding ...

Granules India has received USFDA approval to market a generic medication for major depressive disorder, Bupropion ...

Granules Pharmaceuticals, Inc., a 100% foreign subsidiary of Granules India received the U.S. Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA) of Bupropion ...

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) ...

One in three researchers says their peers force them to carry out tests with animals if their work is to be published, while ...

COUNCIL chiefs have upheld a decision to re-locate Ulverston’s library service despite a consultation being labelled ‘not fair’ ...

The global fight against cancer is intensifying, and with it, the demand for innovative treatments is soaring. One of the ...

The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...